From: A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients
No. Gleason score (%) | |
3 + 4 | 6 (33%) |
4 + 3 | 7 (39%) |
≥ 4 + 4 | 5 (28%) |
No. pathological stage (%) | |
pT2c | 8 (44%) |
pT3a | 7 (39%) |
pT3b | 3 (17%) |
Estimated tumour weight (g) | |
Mean (± SD) | 10.3 (± 4.7) |